An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA

American Journal of Transplantation

Volumn 15, Issue 8, 2015, Pages 2037-2049

  Thomas, K A ^a   Valenzuela, N M ^a   Gjertson, D ^a   Mulder, A ^b   Fishbein, M C ^a   Parry, G C ^c   Panicker, S ^c   Reed, E F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c True North Therapeutics Inc ^*  (United States)

Author keywords

Alloantibody; antibody mediated rejection (ABMR); basic (laboratory) research science; complement biology; fusion proteins and monoclonal antibodies; immunosuppressant; immunosuppression immune modulation; major histocompatibility complex (MHC); organ transplantation in general; pharmacology; translational research science

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; HLA ANTIBODY; MONOCLONAL ANTIBODY; TNT 003; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C1S; HLA ANTIGEN;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART GRAFT; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; CELL CULTURE; CYTOLOGY; HEART TRANSPLANTATION; IMMUNOLOGY; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C1S; ENDOTHELIUM, VASCULAR; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS;

EID: 84937526873     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13273     Document Type: Article

References (97)

1. Cooper NR., The classical complement pathway: Activation and regulation of the first complement component. Adv Immunol 1985; 37: 151-216.
2. Chen G, Chen S, Chen X., Role of complement and perspectives for intervention in transplantation. Immunobiology 2013; 218: 817-827.
3. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al., Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
4. Fishbein GA, Fishbein MC., Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Human Immunol 2012; 73: 1213-1217.
5. Berry GJ, Burke MM, Andersen C, et al., The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32: 1147-1162.
6. Haas M, Sis B, Racusen LC, et al., Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
7. Drachenberg CB, Torrealba JR, Nankivell BJ, et al., Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
8. Freitas MC, Rebellato LM, Ozawa M, et al., The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113-1119.
9. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al., Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
10. Kaneku H, O'Leary JG, Banuelos N, et al., De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
11. Irving C, Carter V, Parry G, Hasan A, Kirk R., Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival. Pediatr Transplant 2011; 15: 193-197.
12. Safavi S, Robinson DR, Soresi S, Carby M, Smith JD., De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014; 33: 1273-1281.
13. Smith JD, Ibrahim MW, Newell H, et al., Pre-transplant donor HLA-specific antibodies: Characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant 2014; 33: 1074-1082.
14. Yerly P, Rotman S, Nobile A, et al., Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation. Transplantation 2015; 99: 586-593.
15. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB., Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transplant 2012; 18: 984-992.
16. Jindra PT, Hsueh A, Hong L, et al., Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008; 180: 2214-2224.
17. Lepin EJ, Zhang Q, Zhang X, et al., Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6: 1560-1571.
18. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF., Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 2002; 168: 5415-5423.
19. Colvin RB, Smith RN., Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
20. Valenzuela NM, Hong L, Shen XD, et al., Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13: 299-311.
21. Valenzuela NM, Mulder A, Reed EF., HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs. J Immunol 2013; 190: 6635-6650.
22. Akiyoshi T, Hirohashi T, Alessandrini A, et al., Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73: 1226-1232.
23. Murata K, Baldwin WM III., Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev 2009; 23: 139-150.
24. Orandi BJ, Zachary AA, Dagher NN, et al., Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014; 98: 857-863.
25. Ghirardo G, Benetti E, Poli F, et al., Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014; 18: E1-E5.
26. Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N., The use of eculizumab in renal transplantation. Clin Transplant 2013; 27: E216-E229.
27. Touzot M, Obada EN, Beaudreuil S, Francois H, Durrbach A., Complement modulation in solid-organ transplantation. Transplant Rev 2014; 28: 119-125.
28. Wohlfahrtova M, Viklicky O., Recent trials in immunosuppression and their consequences for current therapy. Curr Opin Organ Transplant 2014; 19: 387-394.
29. Dawson KL, Parulekar A, Seethamraju H., Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 2012; 31: 1325-1326.
30. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L., Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-1264.
31. Accardo-Palumbo A, Triolo G, Colonna-Romano G, et al., Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. Diabetologia 2000; 43: 1039-1047.
32. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO., Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999; 94: 1673-1682.
33. Stegall MD, Chedid MF, Cornell LD., The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670-678.
34. Stegall MD, Diwan T, Raghavaiah S, et al., Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
35. Burbach M, Suberbielle C, Brocheriou I, et al., Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014; 98: 1056-1059.
36. Bentall A, Tyan DB, Sequeira F, et al., Antibody-mediated rejection despite inhibition of terminal complement. Transplant Int 2014; 27: 1235-1243.
37. Shi J, Rose EL, Singh A, et al., TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015-4022.
38. Mulder A, Eijsink C, Kardol MJ, et al., Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 2003; 171: 6599-6603.
39. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, Bruning H., A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28. Tissue Antigens 1993; 42: 27-34.
40. Park MS, Lau M, Geer LI, Terasaki PI., International sera exchange analyses in relation to DNA sequences: Summary report from 1990 to 1994. Clin Transpl 1994; 1994: 489-508.
41. Navab M, Hough GP, Stevenson LW, Drinkwater DC, Laks H, Fogelman AM., Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J Clin Invest 1988; 82: 1853-1863.
42. Ziegler ME, Jin YP, Young SH, Rozengurt E, Reed EF., HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol 2012; 303: C872-C882.
43. Sicard A, Ducreux S, Rabeyrin M, et al., Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26: 457-467.
44. Berry GJ, Angelini A, Burke MM, et al., The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601-611.
45. Stewart S, Winters GL, Fishbein MC, et al., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
46. AlMahri A, Holgersson J, Alheim M., Detection of complement-fixing and non-fixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens 2012; 80: 404-415.
47. Jane-Wit D, Manes TD, Yi T, et al., Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. Circulation 2013; 128: 2504-2516.
48. Natali PG, De Martino C, Quaranta V, et al., Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation 1981; 31: 75-78.
49. Morris PJ, Ting A., Studies of HLA-DR with relevance to renal transplantation. Immunol Rev 1982; 66: 103-131.
50. Rose ML, Coles MI, Griffin RJ, Pomerance A, Yacoub MH., Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart. Transplantation 1986; 41: 776-780.
51. Fuggle SV, McWhinnie DL, Morris PJ., HLA-class II antigen induction does not exclude a diagnosis of cyclosporine nephrotoxicity. Transplant Proc 1989; 21 (1 Pt 2): 1525-1526.
52. Kroshus TJ, Rollins SA, Dalmasso AP, et al., Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194-1202.
53. Davis EA, Lam TT, Qian Z, Ibrahim S, Baldwin WM III, Sanfilippo FP., Inhibition of neutrophil adhesion and the membrane attack complex of complement synergistically prolongs cardiac xenograft survival. J Heart Lung Transplant 1995; 14: 973-980.
54. Kwan WH, van der Touw W, Paz-Artal E, Li MO, Heeger PS., Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med 2013; 210: 257-268.
55. Li K, Zhou W., Anaphylatoxins in organ transplantation. Semin Immunol 2013; 25: 20-28.
56. Chen G, Sequeira F, Tyan DB., Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849-858.
57. Tyan DB., New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409-415.
58. Lachmann N, Todorova K, Schulze H, Schonemann C., Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013; 95: 694-700.
59. Bartel G, Wahrmann M, Schwaiger E, et al., Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transplant Int 2013; 26: 121-130.
60. Kfoury AG, Hammond ME., Controversies in defining cardiac antibody-mediated rejection: Need for updated criteria. J Heart Lung Transplant 2010; 29: 389-394.
61. Ho EK, Vlad G, Vasilescu ER, et al., Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72: 5-10.
62. Loupy A, Lefaucheur C, Vernerey D, et al., Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
63. Rose ML, Smith JD., Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605-609.
64. Chin C, Chen G, Sequeria F, et al., Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158-163.
65. Terasaki PI, McClelland JD., Microdroplet assay of human serum cytotoxins Nature 1964; 204: 998-1000.
66. Ferrone S, Ting A, Pellegrino MA, Terasaki PI, Reisfeld RA., Utilization of cultured human lymphoid cells for detection of humoral sensitization in prospective recipients of kidney transplants. J Clin Invest 1975; 55: 388-394.
67. Saadi S, Platt JL., Immunology of xenotransplantation. Life Sci 1998; 62: 365-387.
68. Baldwin WM III, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F., Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995; 59: 797-808.
69. Spiller OB., Measurement of C3 fragment deposition on cells. Methods Mol Biol 2000; 150: 131-137.
70. Spiller OB., Measurement of complement lysis of nucleated cells. Methods Mol Biol 2000; 150: 73-81.
71. Watanabe J, Scornik JC., Measuring human complement activation by HLA antibodies. Arch Pathol Lab Med 2006; 130: 368-373.
72. Zeevi A, Lunz J, Feingold B, et al., Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98-105.
73. Thomas KA, Valenzuela NM, Reed EF., The perfect storm: HLA antibodies, complement, FcγRs and endothelium in transplant rejection. Trends Mol Med. In press 2015.
74. Becker EL., The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes. J Exp Med 1972; 135: 376-387.
75. Snyderman R, Phillips J, Mergenhagen SE., Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: Evidence for c5a as the major chemotactic factor. Infect Immun 1970; 1: 521-525.
76. Marder SR, Chenoweth DE, Goldstein IM, Perez HD., Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol 1985; 134: 3325-3331.
77. Molad Y, Haines KA, Anderson DC, Buyon JP, Cronstein BN., Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate l -selectin and beta 2-integrin expression differently. Biochem J 1994; 299 (Pt 3): 881-887.
78. Jagels MA, Daffern PJ, Hugli TE., C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: Epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 2000; 46: 209-222.
79. Albrecht EA, Chinnaiyan AM, Varambally S, et al., C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 2004; 164: 849-859.
80. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC., Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003-1014.
81. Cravedi P, Leventhal J, Lakhani P, Ward SC, Donovan MJ, Heeger PS., Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant 2013; 13: 2530-2539.
82. Strainic MG, Shevach EM, An F, Lin F, Medof ME., Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol 2013; 14: 162-171.
83. Zwirner J, Fayyazi A, Gotze O., Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999; 36: 877-884.
84. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R., Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 2002; 169: 2102-2110.
85. Peng Q, Li K, Anderson K, et al., Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 2008; 111: 2452-2461.
86. Cravedi P, van der Touw W, Heeger PS., Complement regulation of T-cell alloimmunity. Semin Nephrol 2013; 33: 565-574.
87. Tait BD., Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21: 573-577.
88. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB., Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12-17.
89. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB., C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342-347.
90. Visentin J, Vigata M, Daburon S, et al., Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation 2014; 98: 625-631.
91. Diebolder CA, Beurskens FJ, de Jong RN, et al., Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343: 1260-1263.
92. Hughes PD, Cohney SJ., Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr Opin Organ Transplant 2011; 16: 425-433.
93. Hardinger KL, Brennan DC., Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3: 68-77.
94. Jordan SC, Toyoda M, Vo AA., Regulation of immunity and inflammation by intravenous immunoglobulin: Relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7: 341-348.
95. Ahmed T, Senzel L., The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection. J Clin Apher 2012; 27: 173-177.
96. Davis AE III, Lu F, Mejia P., C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010; 104: 886-893.
97. Chang DH, Kittleson MM, Kobashigawa JA., Immunosuppression following heart transplantation: Prospects and challenges. Immunotherapy 2014; 6: 181-194.